Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Fierce Biotech12h
AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
Astra’s Pill Halves High Cholesterol, Raising Blockbuster Hopes
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...
Amgen (AMGN) Receives a Buy from TD Cowen
TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...
Medscape12h
Urticaria Highlights From AAD 2025
Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...
Medscape11h
Hidradenitis Suppurativa Highlights From the American Academy of Dermatology 2025 Annual Meeting
Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...
Healio10h
Tirzepatide improves outcomes in HFpEF, obesity regardless of kidney function
In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...
The Lancet13h
Therapy for mixed dyslipidaemia through ANGPTL3 inhibition
In epidemiological, genetic, and intervention studies, mixed dyslipidaemia, characterised by elevated concentrations of total ...
Healio14h
Ipilimumab plus nivolumab ‘considered a cure’ long term for melanoma brain metastasis
Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...